Relay Therapeutics

OverviewSuggest Edit

Relay Therapeutics is building the world’s first dedicated drug discovery platform centered on protein motion to discover and develop new medicines that will make a transformative difference for patients. By placing protein motion at the heart of drug discovery, Relay is pursuing what it believes will be a fundamental paradigm shift within the pharmaceutical industry, ushering in a new generation of drugs with the potential to improve and extend the lives of millions of patients. Headquartered in Cambridge, Mass., Relay Therapeutics is a private company launched in 2016 with $57 million in Series A venture capital financing from Third Rock Ventures and an affiliate of D.E. Shaw Research. Our world-class team is equal parts bright and bold, with a shared passion for working in intellectually stimulating environments. If you're creative, collaborative and passionate about making a difference in the lives of patients, join us!
TypePrivate
Founded2016
HQCambridge, MA, US
Websiterelaytx.com

Latest Updates

Employees (est.) (Jun 2021)200(+9%)
Job Openings16
Cybersecurity ratingBMore

Key People/Management at Relay Therapeutics

Brian Adams

Brian Adams

General Counsel
Tom Catinazzo

Tom Catinazzo

Vice President, Finance
Don Bergstrom

Don Bergstrom

Executive Vice President, Head of Research and Development
Dorothee Kern

Dorothee Kern

Founder
Mary Mader

Mary Mader

Vice President, Chemistry
Iain Martin

Iain Martin

Vice President, Drug Metabolism and Pharmacokinetics
Show more

Relay Therapeutics Office Locations

Relay Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
399 Binney St 2nd Floor
Show all (1)

Relay Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2016

Relay Therapeutics total Funding

$520 m

Relay Therapeutics latest funding size

$400 m

Time since last funding

2 years ago

Relay Therapeutics investors

Relay Therapeutics's latest funding round in December 2018 was reported to be $400 m. In total, Relay Therapeutics has raised $520 m
Show all financial metrics

Relay Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

Relay Therapeutics Online and Social Media Presence

Embed Graph

Relay Therapeutics News and Updates

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

CAMBRIDGE, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in fireside chats at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021 at 3:50 pm ET and at the JMP Securities Life Science Conference on Thur…

Relay Therapeutics to Participate in Fireside Chat at the Cowen 2nd Annual Oncology Innovation Summit

CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Cowen 2nd Annual Virtual Oncology Innovation Summit on Thursday May 20, 2021 at 11:20am ET. The fireside chat will be webcast live and may be accessed fr…

Relay Therapeutics Strengthens Computational Leadership Team with Addition of Patrick Riley, Ph.D.

Dr. Riley brings extensive experience in artificial intelligence with a focus on drug discovery Dr. Riley brings extensive experience in artificial intelligence with a focus on drug discovery

Relay Therapeutics to Participate in Fireside Chat at Bank of America 2021 Health Care Conference

CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Bank of America 2021 Health Care Conference on Tuesday, May 11, 2021 at 8:45 a.m. ET. The fireside chat will be webcast live and may be accessed from the…

Relay Therapeutics Expands Clinical Leadership Team with Addition of Tara O’Meara and Charles Ferté

Ms. O’Meara and Dr. Ferté bring extensive experience in drug development across oncology and genetic disease Ms. O’Meara and Dr. Ferté bring extensive experience in drug development across oncology and genetic disease

Relay Therapeutics Extends Leadership in Integrating Computational and Experimental Approaches to Create Precision Medicines by Acquiring ZebiAI

Relay Therapeutics’ leadership in this new breed of biotech positions the company as a strategic partner of choice for emerging technologies and founders in these fields
Show more

Relay Therapeutics Frequently Asked Questions

  • When was Relay Therapeutics founded?

    Relay Therapeutics was founded in 2016.

  • Who are Relay Therapeutics key executives?

    Relay Therapeutics's key executives are Brian Adams, Tom Catinazzo and Don Bergstrom.

  • How many employees does Relay Therapeutics have?

    Relay Therapeutics has 200 employees.

  • Who are Relay Therapeutics competitors?

    Competitors of Relay Therapeutics include Mcneil, The Searle Company and Biohaven Pharmaceutical.

  • Where is Relay Therapeutics headquarters?

    Relay Therapeutics headquarters is located at 399 Binney St 2nd Floor, Cambridge.

  • Where are Relay Therapeutics offices?

    Relay Therapeutics has an office in Cambridge.

  • How many offices does Relay Therapeutics have?

    Relay Therapeutics has 1 office.